» Articles » PMID: 18824673

Vanishing MS T2-bright Lesions Before Puberty: a Distinct MRI Phenotype?

Overview
Journal Neurology
Specialty Neurology
Date 2008 Oct 1
PMID 18824673
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple sclerosis (MS) onset before puberty may have a distinct clinical presentation. Pediatric patients with MS may less often meet MRI diagnostic criteria for adults. Whether initial MRI presentation is distinct in prepubertal patients is unknown.

Methods: We queried the UCSF MS database for pediatric patients with MS (onset <or=18 years) who underwent brain MRI within 3 months of initial symptoms. The overall number of lesions and the number of well-defined and ovoid, large, confluent, and gadolinium-enhancing lesions were compared between patients with earlier-onset (EOPMS) (<11 years) and later-onset (LOPMS) (>or=11 years) pediatric MS. The next available brain MRI scan was used to evaluate lesion resolution.

Results: Thirteen children with EOPMS (median age 8.90 years, range [3.58-10.98], 38% girls) and 18 with LOPMS (median age 14.47 years, range [11.78-18.00], 61% girls) were identified. While the overall number of T2-bright lesions was similar in the two groups, patients with EOPMS had fewer well-defined ovoid T2-bright lesions (median = 7, range [0-29] vs 21.5, [4-100]; p = 0.004) and more often had confluent lesions (31% of patients vs 0%; p = 0.02) on their first MRI compared with patients with LOPMS. Ninety-two percent of patients with EOPMS had a reduction in the number of T2-bright lesions on the second scan compared to 29% of patients with LOPMS (p = 0.002).

Conclusions: The distinct prepubertal multiple sclerosis (MS) MRI phenotype suggests that underlying biologic processes may differ in earlier-onset pediatric MS compared to later-onset pediatric MS. These findings may delay diagnosis in that age range. MRI criteria for MS diagnosis may need to be revised before puberty.

Citing Articles

Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment.

Ghezzi A, Neuteboom R Neurol Ther. 2023; 12(6):1867-1881.

PMID: 37682513 PMC: 10630260. DOI: 10.1007/s40120-023-00535-z.


Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.

Redenbaugh V, Chia N, Cacciaguerra L, Mccombe J, Tillema J, Chen J Mult Scler. 2023; 29(7):799-808.

PMID: 37218499 PMC: 10626581. DOI: 10.1177/13524585231166834.


Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.

Fadda G, Waters P, Woodhall M, Brown R, OMahony J, Castro D Mult Scler. 2022; 28(11):1697-1709.

PMID: 35581944 PMC: 9442635. DOI: 10.1177/13524585221093789.


Relapsing neuromyelitis optica in an adolescent girl.

Gupta V, Luthra S, Maheshwari S, Das S BMJ Case Rep. 2021; 14(8).

PMID: 34426420 PMC: 8383875. DOI: 10.1136/bcr-2021-242402.


[Inflammatory diseases of the central nervous system].

Bachhuber A Radiologe. 2021; 61(6):575-585.

PMID: 34105011 DOI: 10.1007/s00117-021-00863-x.